Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept)... ( TARRYTOWN N.Y. May 8 2012 /- Reg...)

Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection

Date:5/8/2012

TARRYTOWN, N.Y., May 8, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) voted against approval of ARCALYST® (rilonacept) Injection for Subcutaneous Use for the proposed indication for the prevention of gout flares in patients initiating uric acid-lowering therapy. The Committee's recommendation will be considered by the FDA in its review of the supplemental Biologics License Application (sBLA) for ARCALYST, but the Committee's recommendation is not binding on the FDA. Regeneron submitted an sBLA for marketing approval of ARCALYST in the United States and has been granted a target date for an FDA decision of July 30, 2012.

Important information about ARCALYST® (rilonacept) Injection
ARCALYST is currently indicated in the U.S. for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. Rilonacept is also approved, but not marketed, in the E.U. for the same patient population. ARCALYST is not approved, but is currently under review by the U.S. FDA, for the prevention of gout flares in patients initiating uric acid-lowering therapy.

IL-1 blockade may interfere with immune response to infections. Serious, life-threatening infections have been reported in patients taking rilonacept. Rilonacept should be discontinued if a patient develops a serious infection. Taking rilonacept with tumor necrosis factor inhibitors is not recommended because this may increase the risk of serious infections. Treatment with rilonacept should not be initiated in patients with active or chronic infections. Patients should not receive a live vaccine while taking rilo
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
2. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
3. Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
4. Regeneron Announces February 2012 Investor Conference Presentations
5. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
6. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
7. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
8. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
9. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
10. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
11. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration

Post Your Comments:

(Date:5/24/2013)... , May 24, 2013 An international roster of ... May 18, in Santa Monica, Calif. ... lung-sparing therapies for MPM, a rare form of cancer ... the pleura, the lining of the chest. ... Blood Institute, the 3rd Annual International Symposium on Lung-Sparing ...

(Date:5/24/2013)... , May 24, 2013 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... recently learned from a public announcement issued by Shanghai ... company listed on Shenzhen Stock Exchange, that on May ... ("Ms. Chan"), one of the shareholders of the ...

(Date:5/24/2013)... -- In accordance with Rule 17.1 and Rule 2.9 of ... States Exchange Act, Echo Pharma Acquisition Limited ("Royalty Pharma") today ... ELN). Background On 2 May 2013, ... the entire of the issued and to be issued share ... On 20 May 2013, Royalty Pharma announced the ...

Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3 China Biologic Comments on the Proposed Shanghai RAAS Transaction 2 China Biologic Comments on the Proposed Shanghai RAAS Transaction 3 China Biologic Comments on the Proposed Shanghai RAAS Transaction 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9

[0] International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma [0] China Biologic Comments on the Proposed Shanghai RAAS Transaction [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements

... YORK, June 15, 2007 /PRNewswire/ -- Telomerase Activation,Sciences, Inc. ... Anti-Aging Trial of TA-65, the first human trial,ever to ... Activator. Statistically significant,results were found in those taking TA-65 ... -- Improvement in immune system function, ...

... Trial Presented at EULAR, BARCELONA, Spain, June ... the European League Against Rheumatism (EULAR),Annual European ... spondylitis (AS) who received REMICADE(R) (infliximab),over two ... addition, REMICADE-treated patients showed sustained,reductions in spinal ...

Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07,Teleconference to Answer Questions About TA-65, Their Telomerase,Activator With Proven Age Management Benefits Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation

(Date:5/25/2013)... 25, 2013 According to a ... Market, 2013–2018", published by MarketsandMarkets is expected to ... of 5.54% which analyzes and studies the major ... Europe, Asia, and Rest of the World. , ... Tables , 87 Figures , ...

(Date:5/25/2013)... According to world-renowned scholars, Queen Cleopatra ... women that ever lived. Cleopatra’s legendary beauty moved nations ... most powerful men in her time. Cleopatra was also ... her skin glowing and fresh, from her legendary milk ... oil and cyprus grass. , Cleopatra was said to ...

(Date:5/25/2013)... May 25, 2013 IBISWorld estimates that revenue ... an average annual rate of 28.7% to $1.0 billion in ... 2013. From 2002 and 2008, no new cell therapy products ... relatively modest growth during that period. In the years since, ... new products. This factor contributed to the industry's fast growth ...

(Date:5/25/2013)... DF (PRWEB) May 25, 2013 Ayurveda ... sanscrit: "knowledge or wisdom of life". While a medical science, ... the transformation of consciousness. Its fundamental philosophy is that disease ... our environment. In order to re-establish optimal health, one must ... adopt a life style which brings us back into perfect ...

(Date:5/25/2013)... 2013 The current residents of Back2Basics - ... the B2B staff all came together Saturday, May 18th to ... of Indian Cuisine, the residents got up to thank Roy ... on their road to recovery, and giving them a second ... center in 2010 after realizing the need for a long-term ...

Breaking Medicine News(10 mins):Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2 Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3 Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4 Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2 Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3 Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 2 Health News:Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld 3 Health News:Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California 2 Health News:Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary 2

[0] Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets [0] The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician [0] Slow Healing: Cell Therapy in the US Industry Market Research Report Now Available from IBISWorld [0] Fundamentos de Ayurveda in Mexico (Ayurvedic Principles) Offered by Escuela de Ayurveda de California [0] Back2Basics Drug and Alcohol Rehabilitation Center Celebrates Their 3rd Anniversary

... Holdings, Inc. (NYSE Alternext US: KUN) ("China Shenghuo" ... previous,announcements, it has filed with the United States ... Report on Form 10-KSB/A for the year,ended December ... 10-Q/A for the,first quarter ended March 31, 2008 ...

... 20 Again next year, the American Pain,Society (APS), ... programs in its acclaimed Clinical Centers of Excellence in ... until Dec. 14,2008. , ... Awards Program,honors forward-thinking teams of healthcare professionals who are ...

... volunteers from State,Farm Bayou Classic(R), organizers from KaBOOM! and residents ... 28 to build a new, safe,playground at the Abramson Science ... is based on drawings provided by,children who attended a Design ... The new playground will provide more than 400 children ...

... Contreras, 61, and Ramon Pichardo, 58, were sentenced today to ... the Medicare program in connection with a $6.8 million HIV ... the Criminal Division and U.S. Attorney R. Alexander Acosta of ... , Judge Federico A. Moreno of ...

... differ by almost $37,000 per patient, study finds , , ... treating colorectal cancer can vary by tens of thousands ... researchers compared the eight most commonly prescribed therapeutic regimens ... ambulatory care centers across the United States. , ...

... in these young adults points to danger, study finds ... the arteries of children of smokers can be detected ... Dutch study finds. , "Smoking in families is harmful ... in many other studies," said research leader Dr. Cuno ...

China Shenghuo Announces Restated Results For Full Year 2007 & First Quarter 2008, Reports Results For Second & Third Quarter 2008 American Pain Society Accepting Applications for Clinical Centers of Excellence in Pain Management Awards State Farm Bayou Classic and KaBOOM! Team Up to Build New Playground in Just One Day Miami Physicians Sentenced to Prison for Their Roles in a $6.8 Million Medicare Fraud Scheme Colorectal Cancer Treatment Costs Vary Widely Parent Smoking During Pregnancy Raises Kids' Heart Risks

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

NPM-ALK, t(2;5) Translocation, Quantitative by RT-PCR, Fluid Nortriptyline by HPLC Norwalk Virus Norpace